John C Byrd

14PUBLICATIONS
190CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursSolid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Jun 25, 2026
Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.

|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

|Apr 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

|Nov 06, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Kerry A Rogers, Pearlly Yan, Ian W Flinn

|Nov 05, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh

Pageof 3

Frequent Collaborators

7 joint publications

Jennifer Woyach

4 joint publications

Kerry A Rogers

4 joint publications

Seema A Bhat

3 joint publications

Alice S Mims